Trial Profile

Vonafexor Fixed Dose-escalation Safety and Proof-of-concept Study in Patients with At Risk of Progression Alport Syndrome

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 12 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vonafexor (Primary)
Indications Hereditary nephritis
Focus Adverse reactions; Proof of concept
Acronyms ALPESTRIA-1
Sponsors ENYO Pharma

Most Recent Events

08 Jan 2026 According to an ENYO Pharma media release, an End-of-Phase 2 meeting is planned for Q2 2026.
08 Jan 2026 Results published in the Media Release
08 Jan 2026 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com